[HTML][HTML] The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: report of a …
R Thoma, M Seneghini, SN Seiffert… - … Resistance & Infection …, 2022 - Springer
Background Despite the adoption of strict infection prevention and control measures, many
hospitals have reported outbreaks of multidrug-resistant organisms (MDRO) during the …
hospitals have reported outbreaks of multidrug-resistant organisms (MDRO) during the …
[HTML][HTML] Impact of respirator versus surgical masks on SARS-CoV-2 acquisition in healthcare workers: a prospective multicentre cohort
…, S Güsewell, T Egger, G Scanferla, R Thoma… - … Resistance & Infection …, 2022 - Springer
Background There is insufficient evidence regarding the role of respirators in the prevention
of SARS-CoV-2 infection. We analysed the impact of filtering facepiece class 2 (FFP2) …
of SARS-CoV-2 infection. We analysed the impact of filtering facepiece class 2 (FFP2) …
[HTML][HTML] Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A …
…, S Moser, IAFM Heijnen, M Trendelenburg, R Thoma… - Trials, 2021 - Springer
Objectives Conestat alfa, a recombinant human C1 esterase inhibitor, is a multi-target inhibitor
of inflammatory cascades including the complement, the kinin-kallikrein and the contact …
of inflammatory cascades including the complement, the kinin-kallikrein and the contact …
[HTML][HTML] Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
…, IAFM Heijnen, M Trendelenburg, R Thoma… - Frontiers in …, 2023 - frontiersin.org
Background Conestat alfa (ConA), a recombinant human C1 inhibitor, may prevent
thromboinflammation. Methods We conducted a randomized, open-label, multi-national clinical trial …
thromboinflammation. Methods We conducted a randomized, open-label, multi-national clinical trial …
Ward-level risk factors associated with nosocomial coronavirus disease 2019 (COVID-19) outbreaks: A matched case–control study
R Thoma, P Kohler, S Haller, J Maenner… - Antimicrobial …, 2022 - cambridge.org
Methods We conducted a matched case–control study in our 700-bed tertiary-care center
during the second wave of the COVID-19 pandemic. Infection prevention and control (IPC) …
during the second wave of the COVID-19 pandemic. Infection prevention and control (IPC) …
Use of respirator vs. surgical masks in healthcare personnel and its impact on SARS-CoV-2 acquisition–a prospective multicentre cohort study
S Haller, S Güsewell, T Egger, G Scanferla, R Thoma… - medRxiv, 2021 - medrxiv.org
Background There is insufficient evidence regarding the role of respirators in the prevention
of SARS-CoV-2 infection. We analysed the impact of filtering facepiece class 2 (FFP2) vs. …
of SARS-CoV-2 infection. We analysed the impact of filtering facepiece class 2 (FFP2) vs. …
Escherichia coli bloodstream infection preceding the diagnosis of rectal carcinoma
R Thoma, P Häuptle, L Degen… - Oxford medical case …, 2018 - academic.oup.com
Background: Cancer is one of the major comorbidities in patients with sepsis, and conversely,
bloodstream infections (BSI) may precede the diagnosis of colorectal malignancy, in …
bloodstream infections (BSI) may precede the diagnosis of colorectal malignancy, in …
Evaluation of Self-Collected Dried Blood Spots for Detection of Sars-Cov-2 Nucleocapsid Antibodies Shows Low Sensitivity
T Dörr, TP Egger, R Thoma, S Nigg… - Available at SSRN …, 2023 - papers.ssrn.com
Background and Aims: Dried blood spots (DBS) have been proposed as a cost-effective
surveillance method for population-wide screening of SARS-CoV-2 immunity but sensitivity of …
surveillance method for population-wide screening of SARS-CoV-2 immunity but sensitivity of …
[PDF][PDF] Molecular mechanisms and cellular implications of microtubule regulation by the von Hippel-Lindau tumor suppressor protein pVHL
CR Thoma - 2009 - research-collection.ethz.ch
The von Hippel-Lindau (VHL) familial cancer syndrome is caused by inactivating germline
mutations of the VHL tumor suppressor gene and is characterized by the development of …
mutations of the VHL tumor suppressor gene and is characterized by the development of …
[PDF][PDF] … , Salomé N. Seiffert2, Danielle Vuichard Gysin3, Giulia Scanferla1, Sabine Haller1, Domenica Flury1, Katia Boggian1, Gian‑Reto Kleger4, Miodrag Filipovic4 …
M Schlegel, P Kohler - Antimicrobial Resistance & …, 2022 - aricjournal.biomedcentral.com
… *Correspondence: marco.seneghini@kssg.ch †Reto Thoma and Marco Seneghini have
contributed equally 1 Division of Infectious Diseases and Hospital Epidemiology, Cantonal …
contributed equally 1 Division of Infectious Diseases and Hospital Epidemiology, Cantonal …